Kintara Therapeutics, Inc. NASDAQ: KTRA and TuHURA Biosciences, Inc. Enter into Definitive Merger Agreement - TuHURA is planning to advance a single Phase 3 trial for IFx-2.0 personalized cancer vaccine as adjunctive therapy with Keytruda? in first-line therapy for advanced Merkel cell carcinoma in 2H 2024 under FDA’s accelerated approval pathway - $31 million subscribed financing by TuHURA in connection with the merger agreement expected to provide cash runway into late 2025 - TuHURA’s first-in-class bifunctional Antibody Drug Conjugates (ADCs) represents potential upside partnering opportunities - Companies are to hold a joint conference call and webcast today, Wednesday, April 3 at 8:30 AM ET https://lnkd.in/dipxQe3A
TuHURA Biosciences, Inc.
生物技术研究
Tampa，Florida 697 位关注者
TuHURA Biosciences, Inc. is a Phase 3 registration-stage immuno-oncology company
关于我们
TuHURA Biosciences, Inc. is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The Company’s technologies are designed to overcome primary and acquired resistance to checkpoint inhibitors or cellular therapies in the treatment of cancer.
- 网站
-
https://tuhurabio.com
TuHURA Biosciences, Inc.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- Tampa，Florida
- 类型
- 私人持股
- 创立
- 1996
地点
-
主要
获取路线
10500 University Center Dr
Suite 110
US，Florida，Tampa，33612
TuHURA Biosciences, Inc.员工
-
Peter O'Neill
Clinical Operations Executive // Using Clinical Trials to deliver potential cures & hope to patients
-
Dennis Yamashita
Chief Scientific Officer and Head Discovery Research and Early Development
-
Lucy DesJardin
Director of Translational Research, Morphogenesis, Inc, Tampa, FL
-
Marina Bastawrous Jacob
Sr. Regulatory Affairs-CMC Manager @ TuHURA Biosciences | Immuno-Oncology
动态
-
TuHURA Biosciences, Inc. Appoints Dennis Yamashita, as Chief Scientific Officer and Head of Discovery Research and Early Development https://lnkd.in/djHCqrAm
TuHURA Biosciences, Inc. Appoints Dennis Yamashita, Ph.D., as Chief Scientific Officer and Head of Discovery Research and Early Development - TuHURA
https://tuhurabio.com
-
#WhatThisMeans: Dr. Jim Bianco, CEO of TuHURA Biosciences, Inc. highlights the Company’s recent corporate transformation that emphasizes their commitment to overcoming major obstacles that limit the effectiveness of cancer #immunotherapies. https://lnkd.in/e8NyMMyz #CancerVaccine #CheckpointInhibitors #MerkelCell #SquamousCell
-
Morphogenesis, Inc. (“Morphogenesis”), a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced its corporate rebranding and provided a business overview. Effective immediately, the company will operate under the name TuHURA Biosciences, Inc. (“TuHURA”). https://lnkd.in/dtzEzPNZ
Morphogenesis, Inc. Announces Corporate Rebranding to TuHURA Biosciences, Inc. and Provides a Business Overview - TuHURA
https://tuhurabio.com